Video: The benefits of partnering with industry
Dr Igor Vivanco leads our Molecular Addictions team, which is working on a variety of projects that could be developed in collaboration with commercial partners.
Cancer cells can become dependent on certain signalling pathways, leaving them unable to survive without some specific oncogenic gene products. They can also become addicted to nutrients, such as glucose and glutamine.
Dr Vivanco’s team is studying these addictions in order to better understand them – and ultimately with the aim of discovering new therapeutic strategies that exploit these vulnerabilities.
In particular, Dr Vivanco’s team has been investigating the molecular basis of addiction to the PI3K signalling pathway, which is altered in the majority of human cancers.
Dr Vivanco has had significant experience in working with industry, and is open to new partnerships, particularly in discovering novel therapeutics, such as antibodies, for targeting these molecular addictions.
Watch more videos of our researchers
Working with pharmaceutical companies
Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.
New partnerships in cancer epigenetics
Sharing experience with industry partners
Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.
Collaborating with commercial partners
Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.
The benefits of partnering with industry
Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.
Exploring new opportunities for collaborative working
Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.